Health ❯Healthcare ❯Clinical Trials ❯Drug Development

Combination Therapy

New Triple-Drug Regimen Boosts Survival in PIK3CA-Mutant HR+ HER2- Breast Cancer

INAVO120 final data show the regimen doubled the time before disease progression compared with standard therapy.

Cancer drug pair extends mouse lifespan by 30% as researchers plan human trials

New Three-Drug Therapy Doubles Survival Time for Advanced Breast Cancer Patients